808744-34-5

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine, 7-bromois used as a building block for the synthesis of various drug candidates due to its unique chemical structure and versatile properties. It plays a crucial role in the development of new pharmaceuticals with potential applications in treating cancer, bacterial infections, and fungal infections.
Used in Agrochemical Industry:
Imidazo[1,2-a]pyridine, 7-bromois used as an intermediate in the synthesis of agrochemicals, particularly those with pesticidal properties. Its unique structure and reactivity make it a valuable component in the development of new agrochemicals to protect crops from pests and diseases.
Used in Medicinal Chemistry Research:
Imidazo[1,2-a]pyridine, 7-bromois used as a key intermediate in medicinal chemistry research for the design and synthesis of novel compounds with potential therapeutic applications. Its unique structure allows for the exploration of various chemical modifications and the evaluation of their biological activities, contributing to the discovery of new drug candidates.
Used in Drug Discovery Efforts:
Imidazo[1,2-a]pyridine, 7-bromois used as a starting material in drug discovery efforts, where its unique chemical properties are exploited to develop new compounds with potential therapeutic effects. Its versatility and reactivity make it an attractive candidate for the synthesis of diverse chemical libraries, facilitating the identification of novel drug candidates with improved efficacy and selectivity.

InChI:InChI=1/C7H5BrN2/c8-6-1-3-10-4-2-9-7(10)5-6/h1-5H

Upstream product

• 107-20-0 2-chloroethanal 
• 84249-14-9 2-amino-4-bromopyridine 

Downstream Products

• 908267-70-9 7-(pyridin-2-yl)imidazo[1,2-a]pyridine 
• 1246184-55-3 7-bromo-3-iodo-imidazo[1,2-a]pyridine 
• 1202701-98-1 (S)-(N-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methylacetamide 
• 1202703-04-5 (R)-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one 
• 1036991-50-0 1-(imidazo[1,2-a] pyridin-7-yl)ethan-1-one 
• 896139-85-8 imidazo[1,2-a]pyridine-7-ol 
• 908268-52-0 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)imidazo[1,2-a]pyridine 
• 1276023-83-6 3-(imidazo[1,2-a]pyridin-7-yl)-4-(4-propoxyphenyl)-1,3-oxazinan-2-one 
• 1276023-79-0 (S)-3-(H-imidazo[1,2-a]pyridin-7-yl)-4-(4-propoxyphenyl)oxazolidin-2-one 
• 1146615-82-8 3-imidazo[1,2-a]pyridine-7-yl-N-methyl-benzamide 
• 1092790-35-6 imidazo[1,2-a]pyridine-7-ylboronic acid 

Relevant academic research and scientific papers

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

Heterocyclic kinase inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a heterocyclic DNA-PK kinase inhibitor compound shown as a general formula (I), a pharmaceutically acceptable salt and an isomer thereof, a pharmaceutical composition and preparation containing the compound, the pharmaceutically acceptable salt and the isomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt and the isomer thereof, and application of the compound, the pharmaceutically acceptable salt and the isomer thereof.

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

FMS-like tyrosine kinase 3 (FLT3) with an internal tandem duplication (ITD) mutation has been validated as a driver lesion and a therapeutic target for acute myeloid leukemia (AML). Currently, several potent small-molecule FLT3 kinase inhibitors are being evaluated or have completed evaluation in clinical trials. However, many of these inhibitors are challenged by the secondary mutations on kinase domain, especially the point mutations at the activation loop (D835) and gatekeeper residue (F691). To overcome the resistance challenge, we identified a novel series of imidazo[1,2-a]pyridine-thiophene derivatives from a NIMA-related kinase 2 (NEK2) kinase inhibitor CMP3a, which retained inhibitory activities on FTL3-ITDD835V and FLT3-ITDF691L. Through this study, we identified the imidazo[1,2-a]pyridine-thiophene derivatives as type-I inhibitors of FLT3. Moreover, we observed compound 5o as an inhibitor displaying equal anti-proliferative activities against FLT3-ITD, FTL3-ITDD835Y and FLT3-ITDF691L driven acute myeloid leukemia (AML) cell lines. Meanwhile, the apoptotic effects of compound supported its mechanism of anti-proliferative action. These results indicate that the imidazo[1,2-a]pyridine-thiophene scaffold is promising for targeting acquired resistance caused by FLT3 secondary mutations and compound 5o is an interesting lead in this direction.

Nitrofuran compound, pharmaceutical composition and preparation method and application of nitrofuran compound

The invention discloses a nitrofuran compound, a pharmaceutical composition and a preparation method and application of the nitrofuran compound. The nitrofuran compound has a structure as shown in a formula (I) (See the specification). The nitrofuran comp

Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors

Never in mitosis (NIMA) related kinase 2 (Nek2) is involved in multiple cellular processes such as cell cycle checkpoint regulation, cell division, DNA damage response and cell apoptosis. Nek2 has been reported to be overexpressed in various tumors and correlated with poor prognosis. Herein, a series of imidazo[1,2-a] pyridines Nek2 inhibitors were designed, synthesized, and their biological activities were investigated. Besides, structure activity relationship analysis of these compounds were performed in the MGC-803 cell. The screening results are promising, and compound 28e shows good proliferation inhibitory activity with an IC50 of 38 nM. The results would be helpful to design and develop more effective Nek2 inhibitors for the treatment of gastric cancer.

1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

Imidazo [1, 2 - a] pyridine derivatives and preparation method and application thereof (by machine translation)

The invention discloses 3 -phenyl imidazo [1, 2 - a] pyridine derivatives represented by a formula (I) or 3 - (thiophene -2 substituted) imidazo [1, 2 - a] pyridine derivatives and a preparation method, and also discloses application. of the 3 -phenyimidazo [1, 2 - a] pyridine derivatives or 3 - (thiophene -2 substituted) imidazo [1, 2 - a] pyridine derivatives as a class of novel structural novel small molecule inhibitors, and the like. (by machine translation)

Imidazo[1,2-a]pyridine compound, and preparation method and applications thereof

The invention discloses an imidazo[1,2-a]pyridine compound, and a preparation method and applications thereof. The imidazo[1,2-a]pyridine compound can inhibit the activity of NEK2 kinases as an NEK2 micro-molecular inhibitor with a novel structure. The in